Identification

Name
Pramocaine
Accession Number
DB09345
Type
Small Molecule
Groups
Approved
Description

Pramocaine (also known as pramoxine or pramoxine HCI) is a topical anesthetic and antipruritic. It is used for many dermatological and anorectal/anogenital conditions including minor cuts/burns, insect bites, hives/rashes due to poison ivy exposure, hemorrhoids and other anorectal/anogenital disorders. Pramocaine is available by itself and in combination with other medications in various topical preparations. It works by preventing ionic fluctuations needed for neuron membrane depolarization and action potential propagation.

Structure
Thumb
Synonyms
  • Pramoxine
Product Ingredients
IngredientUNIICASInChI Key
Pramoxine hydrochloride88AYB867L5637-58-1SYCBXBCPLUFJID-UHFFFAOYSA-N
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aveeno Active Naturals Skin Relief Medicated Anti Itch TreatmentCream5 mg/gTopicalJohnson & Johnson Consumer Products Company, Division Of Johnson Consumer Companies, Inc.2011-09-072017-07-01Us
Bikini Zone MEDICATED After Shave Fresh ScentSpray10 mg/mLTopicalCca Industries, Inc2013-08-01Not applicableUs
Bikini Zone Medicated After Shave SprayLiquid1 %TopicalCca Industries, IncNot applicableNot applicableCanada
Bikini Zone Medicated After-shave Roll-ON ReliefLiquid1 %TopicalCca Industries, IncNot applicableNot applicableCanada
CeraVe Itch Relief MoisturizingLotion1 mg/mLTopicalValeant Pharmaceuticals North America2016-01-18Not applicableUs
CeraVe Itch Relief Moisturizing CreamCream10 mg/gTopicalValeant Pharmaceuticals North America2016-02-01Not applicableUs
CocoskinCream1.18 mg/mLTopicalNet Source, Llc2016-04-01Not applicableUs
CurasoreLiquid1 g/100mLTopicalS.S.S. Company1995-08-31Not applicableUs
CVS Fragrance Free Anti-ItchLotion10 mg/mLTopicalCVS Health2010-07-08Not applicableUs
CVS Fragrance Free Anti-ItchLotion10 mg/mLTopicalRite Aid2010-07-08Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acella Hydrocortisone Acetate - Pramoxine SinglesPramocaine (1 g/100g) + Hydrocortisone acetate (2.5 g/100g)CreamTopicalAcella Pharmaceuticals, LLC2010-11-082017-08-17Us
Analpram AdvancedPramoxine hydrochloride + Hydrocortisone acetateKitSebela Pharmaceuticals Inc.2010-10-012017-02-28Us
Analpram AdvancedPramoxine hydrochloride + Hydrocortisone acetateKitFerndale Laboratories, Inc.2010-10-012016-04-30Us
Analpram AdvancedPramoxine hydrochloride + Hydrocortisone acetateKitOralSebela Pharmaceuticals Inc.2010-10-012017-02-23Us
Analpram AdvancedPramoxine hydrochloride + Hydrocortisone acetateKitFerndale Laboratories, Inc.2010-08-012016-11-30Us
Analpram AdvancedPramoxine hydrochloride + Hydrocortisone acetateKitSebela Pharmaceuticals Inc.2010-08-012017-02-28Us
Analpram AdvancedPramoxine hydrochloride + Hydrocortisone acetateKitFerndale Laboratories, Inc.2010-10-012016-12-31Us
Analpram EPramoxine hydrochloride + Hydrocortisone acetateKitFerndale Laboratories, Inc.2009-09-012016-05-31Us
Analpram EPramoxine hydrochloride (10 mg/g) + Hydrocortisone acetate (25 mg/g)CreamTopicalFerndale Laboratories, Inc.2009-06-302017-12-31Us
Analpram EPramoxine hydrochloride + Hydrocortisone acetateKitFerndale Laboratories, Inc.2009-09-012016-05-31Us
Categories
UNII
068X84E056
CAS number
140-65-8
Weight
Average: 293.407
Monoisotopic: 293.199093733
Chemical Formula
C17H27NO3
InChI Key
DQKXQSGTHWVTAD-UHFFFAOYSA-N
InChI
InChI=1S/C17H27NO3/c1-2-3-12-20-16-5-7-17(8-6-16)21-13-4-9-18-10-14-19-15-11-18/h5-8H,2-4,9-15H2,1H3
IUPAC Name
4-[3-(4-butoxyphenoxy)propyl]morpholine
SMILES
CCCCOC1=CC=C(OCCCN2CCOCC2)C=C1

Pharmacology

Indication

It is indicated for temporary relief of pain and pruritus from minor lip and skin irritations as well as for temporary relief from pain, burning, itching and discomfort associated with hemorrhoids and other anorectal/anogenital disorders.

Structured Indications
Pharmacodynamics

Pramocaine temporarily relieves pain, pruritis, burning and discomfort associated with minor lip and skin irritations and hemorrhoid's by inhibiting voltage gated sodium channels on neurons.

Mechanism of action

Pramocaine reversibly binds and inhibits voltage gated sodium channels on neurons decreasing sodium permeability into the cell. This stabilizes the membrane and prevents ionic fluctuations needed for depolarization stopping any action potential propagation.

TargetActionsOrganism
AVoltage gated sodium channel
antagonist
inhibitor
human
Absorption

There is minimal absorption after topical administration and it is not given orally.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

LD50 Mouse ip 300 mg/kg, LD50 Mouse sc 750 mg/kg

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Pramocaine.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Pramocaine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pramocaine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Pramocaine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pramocaine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Pramocaine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Pramocaine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Pramocaine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pramocaine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Pramocaine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pramocaine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Pramocaine.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pramocaine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Pramocaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Pramocaine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Azaperone.Investigational, Vet Approved
AzelastinePramocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Pramocaine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Pramocaine.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Pramocaine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Pramocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Pramocaine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pramocaine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pramocaine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Pramocaine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Pramocaine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Pramocaine.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pramocaine.Approved, Investigational
BuprenorphinePramocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pramocaine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pramocaine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Pramocaine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Pramocaine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Pramocaine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pramocaine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Pramocaine.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pramocaine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Pramocaine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Pramocaine is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pramocaine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pramocaine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Pramocaine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pramocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pramocaine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pramocaine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pramocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Pramocaine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Pramocaine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pramocaine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Pramocaine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Pramocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pramocaine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pramocaine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pramocaine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Pramocaine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Pramocaine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pramocaine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pramocaine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pramocaine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Pramocaine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Pramocaine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Pramocaine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Pramocaine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pramocaine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pramocaine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pramocaine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Pramocaine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pramocaine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pramocaine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Pramocaine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Pramocaine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Pramocaine.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Pramocaine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pramocaine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Pramocaine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Pramocaine is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pramocaine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Pramocaine is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Pramocaine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Pramocaine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pramocaine.Approved
EthanolPramocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pramocaine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pramocaine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Pramocaine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pramocaine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Pramocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Pramocaine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Pramocaine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pramocaine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Pramocaine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Pramocaine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pramocaine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pramocaine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Pramocaine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pramocaine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Pramocaine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pramocaine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pramocaine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pramocaine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pramocaine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Pramocaine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Pramocaine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Pramocaine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Pramocaine.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pramocaine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Pramocaine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Pramocaine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Pramocaine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Pramocaine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Pramocaine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pramocaine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Pramocaine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Pramocaine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pramocaine.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Pramocaine.Approved, Investigational
HydrocodonePramocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pramocaine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Pramocaine is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Pramocaine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pramocaine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pramocaine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pramocaine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Pramocaine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Pramocaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Pramocaine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pramocaine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Pramocaine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pramocaine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Pramocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Pramocaine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Pramocaine.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Pramocaine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pramocaine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Pramocaine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pramocaine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pramocaine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Pramocaine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Pramocaine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Pramocaine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Pramocaine.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pramocaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pramocaine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Pramocaine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pramocaine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Pramocaine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Pramocaine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Pramocaine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Pramocaine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Pramocaine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pramocaine.Approved
MethotrimeprazinePramocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pramocaine.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Pramocaine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pramocaine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pramocaine.Approved
MetyrosinePramocaine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Pramocaine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Pramocaine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved, Investigational
MirtazapinePramocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Pramocaine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Pramocaine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pramocaine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pramocaine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Pramocaine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pramocaine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pramocaine.Approved
OpiumThe risk or severity of adverse effects can be increased when Pramocaine is combined with Opium.Approved, Illicit
OrphenadrinePramocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Pramocaine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pramocaine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pramocaine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pramocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pramocaine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pramocaine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pramocaine.Approved
ParaldehydePramocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Pramocaine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pramocaine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pramocaine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
PerazineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Pramocaine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pramocaine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pramocaine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Pramocaine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pramocaine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pramocaine is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Pramocaine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Pramocaine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Pramocaine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Pramocaine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pramocaine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pramocaine is combined with Pomalidomide.Approved
PramipexolePramocaine may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Pramocaine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pramocaine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Pramocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Pramocaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pramocaine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Pramocaine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Pramocaine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pramocaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Pramocaine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Pramocaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Pramocaine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Pramocaine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Pramocaine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pramocaine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Pramocaine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pramocaine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pramocaine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pramocaine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Pramocaine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Romifidine.Vet Approved
RopinirolePramocaine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pramocaine.Approved
RotigotinePramocaine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pramocaine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pramocaine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Pramocaine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pramocaine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Pramocaine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pramocaine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pramocaine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Pramocaine is combined with Sultopride.Experimental
SuvorexantPramocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tasimelteon.Approved
Technetium Tc-99m tilmanoceptPramocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pramocaine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Pramocaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Pramocaine.Investigational
ThalidomidePramocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pramocaine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Pramocaine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pramocaine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pramocaine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Pramocaine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pramocaine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pramocaine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pramocaine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Pramocaine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Pramocaine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Pramocaine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pramocaine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Pramocaine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pramocaine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pramocaine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Pramocaine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Pramocaine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Pramocaine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pramocaine.Approved
XenonThe risk or severity of adverse effects can be increased when Pramocaine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pramocaine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pramocaine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Pramocaine is combined with Zolazepam.Vet Approved
ZolpidemPramocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Pramocaine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Pramocaine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Pramocaine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pramocaine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Pubchem [Link]
External Links
KEGG Compound
C07892
PubChem Compound
4886
PubChem Substance
310265219
ChemSpider
4717
ChEBI
8357
ChEMBL
CHEMBL1198
HET
PX9
Wikipedia
Pramocaine
ATC Codes
C05AD07 — PramocaineD04AB07 — Pramocaine
AHFS Codes
  • 84:08.00 — Antipruritics and Local Anesthetics
PDB Entries
4y0q / 4y0r / 4y0s

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentPlasma Cell Myeloma1
3CompletedTreatmentCommunity Acquired Infections / Infections, Gram-Positive Bacterial / Pneumonia, Pneumococcal1
4CompletedDiagnosticColonoscopy1
4CompletedTreatmentColorectal Cleansing Prior Operation1
4CompletedTreatmentFunctional Dyspepsia / Helicobacter Pylori / Peptic Ulcers1
4CompletedTreatmentHelicobacter Pylori Treatment Failure1
4CompletedTreatmentIndigestion / Peptic Ulcers1
4CompletedTreatmentPyelonephritis1
4CompletedTreatmentVertebral Osteomyelitis1
4RecruitingPreventionPostoperative Infections1
4Unknown StatusTreatmentPruritis1
4WithdrawnPreventionComplications; Breast Prosthesis, Infection or Inflammation1
Not AvailableCompletedNot AvailableDiverticulitis1
Not AvailableCompletedNot AvailableHealthy Volunteers / High Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailablePenicillin Allergy1
Not AvailableCompletedPreventionInfection NOS1
Not AvailableCompletedScreeningColorectal Cancers1
Not AvailableCompletedTreatmentDiverticulitis, Colonic1
Not AvailableEnrolling by InvitationTreatmentAcute Appendicitis1
Not AvailableRecruitingTreatmentLiver Cirrhosis / Small Intestinal Bacterial Overgrowth1
Not AvailableWithdrawnNot AvailableCystic Fibrosis (CF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Kit
KitOral
SuppositoryRectal
CreamTopical5 mg/g
Liquid; sprayTopical
LiquidTopical1 %
StickTopical
Aerosol, sprayTopical
CreamTopical1.18 mg/mL
LiquidTopical1 g/100mL
ClothTopical1 mg/1
SprayTopical
LiquidTopical
CreamTopical1 g/57g
SuspensionTopical1 %
CreamTopical10 mg/g
StickTopical1.0 %
CreamTopical1 %
ClothTopical
CreamRectal; Topical
CreamTopical
OintmentTopical
OintmentRectal
GelTopical
LotionTopical10 1/mL
CreamRectal
LotionTopical10 mg/mL
ClothTopical10 mg/1000mg
SwabTopical1 %
LotionTopical
Aerosol, foamTopical10 mg/g
Solution / dropsAuricular (otic)
SwabTopical10 mg/g
OintmentRectal; Topical
AerosolRectal
Aerosol, foamTopical
Aerosol, foamRectal150 mg/15g
LotionTopical1 mg/mL
ClothTopical10 mg/g
CreamTopical0.5 %
SolutionTopical1 %
CreamRectal; Topical; Vaginal1 %
SprayTopical10 mg/mL
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.221 mg/mLALOGPS
logP3.03ALOGPS
logP2.84ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)7.06ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area30.93 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity84.82 m3·mol-1ChemAxon
Polarizability35.11 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0ufu-5900000000-594926332aad338cf632
GC-MS Spectrum - CI-BGC-MSsplash10-0fb9-0920000000-809db2c1fd1e2472e79c
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0090000000-7c9bc5e2393574b551ac
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0290000000-4c336a718a063e0c4bd2
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0910000000-5d6f0b2eda70998496cd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-1900000000-6dba3652b26250fc34b5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-3900000000-cb727bd5218a44669d18
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-6900000000-d132e77318e9757c12bc
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0zmi-9400000000-4e4a238aa95af1cb797e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ab9-9100000000-e81d251a19a7e8af2df6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9000000000-3c9f67d2e404ef8d5770

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Alkyl aryl ethers / Morpholines / Trialkylamines / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenoxy compound / Phenol ether / Alkyl aryl ether / Monocyclic benzene moiety / Morpholine / Oxazinane / Tertiary amine / Tertiary aliphatic amine / Dialkyl ether / Ether
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
aromatic ether, morpholines (CHEBI:8357)

Targets

1. Voltage gated sodium channel
Kind
Protein group
Organism
human
Pharmacological action
Yes
Actions
Antagonist
Inhibitor
References
  1. PubChem [Link]

Drug created on November 27, 2015 13:50 / Updated on December 10, 2017 17:18